Clinical trials sponsored by Chong Kun Dang Pharmaceutical

Phase breakdown

Conditions studied

Recruiting trials led by Chong Kun Dang Pharmaceutical

• A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.
  NCT07358156 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 2 locations
• Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes
  NCT06838286 · Phase: Not specified · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants
  NCT07258745 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
  NCT06643819 · Phase: Phase 3 · Ages: 19 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials is Chong Kun Dang Pharmaceutical recruiting for?

Chong Kun Dang Pharmaceutical is the lead sponsor of 4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.